3^rd European Congress on Hematology and Blood Disorders

COVID-19 is a systemic disease with a significant impact on the hematopoietic system and hemostasis. Patients with cancer may be huge susceptible to and have higher morbidity and mortality rates from COVID-19 than the general population, while epidemiologic data specifically addressed to hematologic patients are limited. The prevalence of COVID-19 in hematologic patients, mostly affected by malignancies, was not significantly higher compared to that of the general population. The revision enlightens on the epidemiology, risk factors and outcomes of COVID-19 among patients with HM. While the COVID-19 vaccinations will lead to a marked reduction of infections in HM patients, the possibility of a lower efficacy of vaccinations needs to be taken into account and possibly resembling previous experiences with influenza vaccination.